CLLSCellectis S.A.

Nasdaq cellectis.com


$ 3.09 $ 0.00 (0 %)    

Friday, 03-May-2024 15:59:53 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 2.99
$ 2.97
$ 0.00 x 0
$ 0.00 x 0
$ 2.97 - $ 3.09
$ 0.96 - $ 3.77
90,809
na
214.54M
$ 2.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cellectis-appoints-arthur-stril-as-interim-chief-financial-officer-replacing-mr-bing-wang

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

 cellectis-q4-2023-gaap-eps-064-misses-026-estimate-sales-1990m-miss-16263m-estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.26) b...

 cellectis-announces-two-poster-presentations-on-novel-talen-editing-process-for-gene-correction-and-gene-insertion-in-hspcs-at-the-asgct-annual-meeting

Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platf...

 cellectis-q3-2023-adj-eps-036-beats-042-estimate-sales-164m-miss-358m-estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by ...

 earnings-scheduled-for-november-6-2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on ...

 earnings-preview-cellectis
Earnings Preview: Cellectis
11/03/2023 19:01:17

 cellectis-to-present-preliminary-results-of-nathali01-and-updated-results-of-the-balli01-phases-i-trials-at-the-american-society-of-hematology--65th-annual-meeting

 Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing plat...

 why-staar-surgical-shares-are-trading-lower-by-around-16-here-are-other-stocks-moving-in-thursdays-mid-day-session

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was a...

 why-roku-shares-are-trading-higher-by-around-19-here-are-20-stocks-moving-premarket

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. L...

 dow-gains-over-100-points-fed-leaves-interest-rates-unchanged

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision. The Dow traded u...

 why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers

 why-is-cancer-player-cellectis-stock-trading-over-100-higher-today

Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company 

 jmp-securities-reiterates-market-outperform-on-cellectis-maintains-6-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price ta...

 nasdaq-surges-over-100-points-ahead-of-fed-decision-wework-shares-plunge

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow...

 us-stocks-mixed-private-sector-payrolls-increase-less-than-expected

U.S. stocks traded mixed this morning, ahead of interest rate decision from the Federal Reserve. Following the market opening ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION